Use of Tinzaparin for Anticoagulation in Hemodialysis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 191 participants.

Also called NCT01930396

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 191 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01930396
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01930396. Randomized; quadruple masking; primary purpose prevention. Start 2013-09 (registry gives no type); primary completion 2016-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of Tinzaparin for Anticoagulation in Hemodialysis
Acronym
HEMO-TIN
Condition
Kidney Failure, Chronic
Intervention (Drug)
Tinzaparin
Intervention (Drug)
Unfractionated Heparin
Intervention (Drug)
Placebo (for Tinzaparin)
Intervention (Drug)
Placebo (for Unfractionated Heparin)
Lead sponsor
Christine Ribic (class: other)
Collaborator
McMaster University (class: other)
Collaborator
LEO Pharma (class: industry)

Record details

Record id
cardio:ct-nct01930396
Content hash
8e5c4b0e45471b9b981832394da570d5da475e830199b9da2928bcb9eca7e4f1